Hiv Vaccine Articles & Analysis
11 news found
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near ...
(NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced preclinical data, in collaboration with Gilead Sciences, Inc., on arenaviral therapeutic vaccines that are being studied as a component of a potential functional curative regimen for human immunodeficiency virus ...
Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead Independent Director and a leading biotechnology entrepreneur and investor, joins OPKO’s Board of Directors OPKO Health, Inc. ...
INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Oce for Chemical, Biological, ...
INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 trial. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, ...
INOVIO has clinically shown that a DNA vaccine candidate can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. ...
INOVIO plans to test clinical samples from our INO-4800 vaccine candidate as well as our Pan-COVID-19 vaccine candidate INO-4802 against the Omicron variant to assess the generation of immune responses, with data expected in the coming weeks. ...
The trial will assess whether INO-4201 can be used as a booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (Ervebo®1), an FDA- and EMA-approved viral-based vector Ebola vaccine. ...
INOVIO's vaccine candidates do not interfere with or change in any way an individual's own DNA. The potential advantages of INOVIO's vaccine platform include how quickly DNA vaccine candidates can be designed and manufactured; the stability of the vaccine candidates, which do not require freezing in storage and transport; and the ...
“Achieving this critical milestone provides validation toward not only serving this unprecedented global crisis, but also provides invaluable support toward our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide.” Before the pandemic, POP Bio primarily focused on developing cancer ...
"One issue is that, although computers are ubiquitous across Africa, high-speed Internet is not," said Hakeem Oluseyi, interim president of the society. More>> HIV vaccine trial starts in South Africa Research to establish whether a vaccine can stem progression of disease in people already infected with HIV has started at ...